Evaluate Tolerability of a Multi-envelope, Prime-boost HIV Vaccine in Healthy Adults
Summary
Vaccines have been very successful in preventing viral infections such as hepatitis B and the measles. Viral vaccines work by causing a person's immune system to make cells that will work against the virus. Due to the success in treating other viral infections, scientists are trying to develop a vaccine for human immunodeficiency virus (HIV). HIV infection is the cause of acquired immune deficiency syndrome (AIDS). AIDS is one of the most serious viral infections we know. This is a research study to evaluate the safety of a possible vaccine against HIV. Researchers want to determine that a person's immune system can respond to the HIV before he or she is exposed to it. Therefore that person may be able to be protected from infection with HIV.
Timeline
- Start
- 2007-05
- Primary completion
- 2008-01
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EnvDNA | Vaccine | 100 ug | Intramuscular |
| Subject | EnvPro | Vaccine | 100 ug | Intramuscular |
| Subject | PolyEnv1 | Vaccine | 107 unknown | Subcutaneous |